T
Tanja Steiner
Researcher at University of Sheffield
Publications - 6
Citations - 141
Tanja Steiner is an academic researcher from University of Sheffield. The author has contributed to research in topics: Alternative complement pathway & Properdin. The author has an hindex of 4, co-authored 5 publications receiving 121 citations.
Papers
More filters
Journal ArticleDOI
TRAIL attenuates the development of atherosclerosis in apolipoprotein E deficient mice
Victoria Watt,Janet Chamberlain,Tanja Steiner,Sheila E. Francis,David C. Crossman,David C. Crossman +5 more
TL;DR: It is concluded that TRAIL attenuates plaque size at early stages of atherosclerosis, as a result of increased smooth muscle cells in lesions of TRAIL deficient, pro-atherosclerotic animals.
Journal ArticleDOI
Vessel wall, not platelet, P2Y12 potentiates early atherogenesis
TL;DR: Ticagrelor and clopidogrel effectively reduced platelet reactivity but were unable to inhibit early atherogenesis, demonstrating that these P2Y12 inhibitors may not be effective in preventing early disease.
Journal ArticleDOI
Protective Role for Properdin in Progression of Experimental Murine Atherosclerosis
Tanja Steiner,Lorenza Francescut,S. Byrne,Timothy R. Hughes,Archana Jayanthi,Irina A. Guschina,John L. Harwood,Katherine Cianflone,Cordula M. Stover,Sheila E. Francis +9 more
TL;DR: It is concluded that properdin plays an unexpectedly beneficial role in the development and progression of early atherosclerotic lesions.
Journal ArticleDOI
The role of complement in the development and manifestation of murine atherogenic inflammation: novel avenues.
Lorenza Francescut,Tanja Steiner,S. Byrne,Katherine Cianflone,Sheila E. Francis,Cordula M. Stover +5 more
TL;DR: A critical overview of existing models is given, seemingly conflicting results obtained with complement-deficient mouse models are analyzed, the importance of interrelationships between pro-coagulpant activity, adipose tissue, macrophages and complement is highlighted, and exciting avenues of topical research are uncovered.
Journal ArticleDOI
A36 investigating type 1 regulatory t cells as a therapy for inflammatory bowel disease using a mouse model of acute intestinal epithelial damage
TL;DR: In this article , type 1 regulatory cells (Tr1s) were used to prevent inflammatory damage and fibrosis in an mouse model of acute gut damage, and the results indicated no significant differences in inflammatory cell infiltrate scores between control and Tr1 treated mice.